CLINICAL TRIALS AND OBSERVATIONS Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
نویسندگان
چکیده
1Department of Internal Medicine II, Division of Hematology and Medical Oncology, University Hospital Wuerzburg and Early Clinical Development Unit of Comprehensive Cancer Center Mainfranken (CCCM), Wuerzburg; 2Department of Hematology/Oncology, HELIOS Klinikum Berlin Buch, Berlin; 3Department of Internal Medicine III, University Hospital, Ulm; 4Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden; 5Department of Hematology and Oncology, Charité University Hospital, Berlin; 6Celgene Germany, Munich; and 7CCCM, Wuerzburg, Germany
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
1Department of Lymphoma and Myeloma, M. D. Anderson Cancer Center, Houston, TX; 2Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece; 3Department of Medicine, Princess Margaret Hospital, Toronto, ON; 4Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universit...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma Paul G. Richardson, Wanling Xie, Sundar Jagannath, Andrzej Jakubowiak, Sagar Lonial, Noopur S. Raje, Melissa Alsina, Irene M. Ghobrial, Robert L. Schlossman, Nikhil C. Munshi, Amitabha Mazumder, David H. Vesole, Jonathan L. Kaufman, Kathleen Colson, Mary McKenney, Laura E. Lu...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
1Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA; 2Myeloma Program, Karmanos Cancer Institute, Detroit, MI; 3University of Pittsburgh Medical Center Cancer Centers, Pittsburgh, PA; 4Biostatistics Facility, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA; and 5College of ...
متن کاملMultidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.
Verapamil was evaluated as a chemosensitizer for reversing multidrug resistance in multiple myeloma both in vitro and in clinical trials. Bone marrows from 59 myeloma patients in relapse were evaluated for several resistance parameters: expression of p-glycoprotein (MDR1), doxorubicin (Adriamycin) and vincristine sensitivity, and the ability of added verapamil to reduce resistance to the cytoto...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
1Haematology Department, Peter MacCallum Cancer Centre, East Melbourne, Australia; 2University of Melbourne, Melbourne, Australia; 3Haematology Immunology Translational Research Laboratory, Research Division, Peter MacCallum Cancer Centre, East Melbourne, Australia; 4Faculty of Medicine, Monash University, Victoria, Australia; 5Haematology Service, Monash Medical Centre, Melbourne, Australia; 6...
متن کامل